Promis Neurosciences (NASDAQ:PMN) Issues Earnings Results

Posted by Brenda Bartman on May 13th, 2026

Promis Neurosciences (NASDAQ:PMN – Get Free Report) released its quarterly earnings results on Monday. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.20), FiscalAI reports.

Promis Neurosciences Stock Performance

Promis Neurosciences stock traded up $0.16 during mid-day trading on Wednesday, reaching $10.65. The company’s stock had a trading volume of 2,814 shares, compared to its average volume of 130,757. Promis Neurosciences has a 12-month low of $6.27 and a 12-month high of $39.75. The company has a market capitalization of $95.51 million, a P/E ratio of -0.56 and a beta of -0.20. The firm’s fifty day moving average price is $14.82 and its two-hundred day moving average price is $12.00.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PMN. Wall Street Zen downgraded Promis Neurosciences to a “strong sell” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Promis Neurosciences in a research report on Thursday, January 22nd. Finally, Guggenheim lowered their price target on shares of Promis Neurosciences from $125.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Promis Neurosciences has an average rating of “Hold” and a consensus price target of $26.50.

Get Our Latest Stock Analysis on Promis Neurosciences

Insider Transactions at Promis Neurosciences

In other news, Director Patrick D. Kirwin purchased 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 22nd. The shares were purchased at an average price of $11.33 per share, with a total value of $45,320.00. Following the completion of the acquisition, the director owned 4,653 shares in the company, valued at $52,718.49. This trade represents a 612.56% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Johanne Kaplan purchased 1,629 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was purchased at an average cost of $15.35 per share, for a total transaction of $25,005.15. Following the acquisition, the insider owned 3,941 shares of the company’s stock, valued at approximately $60,494.35. This trade represents a 70.46% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 8,629 shares of company stock valued at $140,855. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Promis Neurosciences stock. Citadel Advisors LLC lifted its position in Promis Neurosciences (NASDAQ:PMN – Free Report) by 168.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 170,079 shares of the company’s stock after purchasing an additional 106,650 shares during the quarter. Citadel Advisors LLC owned about 0.32% of Promis Neurosciences worth $72,000 at the end of the most recent quarter. Institutional investors and hedge funds own 50.13% of the company’s stock.

About Promis Neurosciences

(Get Free Report)

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.